Promoting Safe Use of OTC Products Lessons from Health Literacy Research

Michael Wolf, PhD MPH

Professor, Associate Division Chief General Internal Medicine & Geriatrics Northwestern University Chicago, IL





Disclosures

<u>Federal</u>

- NIH
 - NCI
 - NIA
 - NIDDK
 - NINR
 - NHLBI
 - OBSSR
- AHRQ
- FDA

<u>Private</u>

- ACOG
- California Endowment
- California Healthcare Foundation
- Missouri Foundation for Health
- PCORI

Industry

- Abbvie
- Amgen
- Deborah Adler Design
- Eli Lilly
- Emmi Solutions
- Luto UK
- Merck
- UnitedHealthcare
- Vivus





1. OTC Products offer public health benefit if patients properly self-select & safely use them.

- Monograph products receive GRASE determination with assumption that OTC labeling ensures a consumer's appropriate use of a product when self-treating.





2. People vary – by education, literacy level, self-care experience, culture & beliefs, symptom tolerance.

- How consumers actually use (or misuse) OTC monograph-covered products may not be as expected when receiving GRASE determination.








Some Unique OTC Challenges

- No 'learned intermediary'
 - Consumer self-selection
- # of Product Choices
 - Brand + Generic Options
 - Single & Multi-Ingredient Products
- Problematic Labeling
- Clarity, understandability
- Front-of-package, Drug Facts, container vs. package
- Size of font, information sequence

National Assessment of Adult Health Literacy, 2003








228

Identify three substances that may interact with an over-the-counter drug to cause a side effect, using information on the over-the-counter label



Limited Health Literacy (43% of adults)

3. Marketing practices for OTC products focus consumers on symptom targets, not active ingredients.

- Consumers may properly self-select an OTC product to treat symptom, but lack awareness of what they are taking.





4. "Therapeutic Misadventures" happen with OTC products.

- Consumers (intentionally and unintentionally) misuse OTCs
 - exceed maximum daily dose
 - double-dip
 - incorrectly self-titrate dose intervals
 - over-medicate with multi-ingredient OTC products
- OTC labeling a root cause





Unintentional Misuse


- Half (52.9%) of adults lack awareness of OTC risks (Miller 2014)
- 1 in 4 (24%) adults take more than recommended max dose for one OTC product (Wolf et al 2012)
- Nearly half (46%) of adults misuse OTC products by concomitant use (Wolf et al 2012)


Better OTC surveillance, safety review, and responses are necessary.

- Increasing FDA resources might improve currently recognized issues:
 - recognition of OTC product concerns
 - timeliness of policy decision-making on updates to monographs
 - Ability to fast-track safety innovations









Improving Review Benefits All

- Justification for OTC vs. prescriptions based on labeling, ability of consumers to self-care
- Consumers presently have inadequate support for OTC decision making and safe use, disparities exist
- Reasons for an FDA expanded review program are well defined (see Federal Register)
- Performance goals should include consumer-centered outcomes (i.e. awareness, self-reported use, etc.)

Health Literacy & Learning Program

Michael Wolf, MA MPH PhD
Professor, Medicine & Learning Sciences
Vice Chair – Research, Dept. of Medicine
Associate Division Chief – Research
General Internal Medicine & Geriatrics
mswolf@northwestern.edu